Robert Wicke joined Omniome in 2020 as the Chief Executive Officer. Robert has over 30 years of leadership experience at life science instrumentation and technology companies. Prior to Omniome, Robert held the role of CEO for Halo Labs where his team launched revolutionary tools for biologics researchers, secured multiple rounds of funding and relocated the corporate headquarters.

As General Manager at Pall ForteBio, Robert was responsible for growing the company with consistent growth exceeding 25% growth for four years. Robert was the Senior VP of Instrumentation R&D at Pall Corporation and a corporate M&A member, helping acquire a variety of companies into Pall’s numerous markets. Before Pall, Robert was VP of Product Development and Operations for ForteBio where he helped exit the company to Pall Corporation for over $160M.

Robert held leadership roles on the executive team at Molecular Devices Corporation where he helped acquire MDS for $615M. Previously he was at Axon Instruments, Inc. for 13 years as Vice President of Software Engineering, helping be the first private company to IPO on the Australian stock market, and then helped with the $140 million acquisition by Molecular Devices.

Robert received a BA in Computer and Information Sciences and Mathematics from Drew University, NJ and an MS in Computer and Information Sciences from the University of Oregon.